joko tri atmojo; Vivi Erlina Maylanda; Aprilia Tina Prastiwi; Aquartuti Tri Darmayanti; Saras Kuntari

doi:10.31290/jiki.v5i2.1492

joko tri atmojo stikes mamba ul ulum surakarta
Vivi Erlina Maylanda
Aprilia Tina Prastiwi
Aquartuti Tri Darmayanti
Saras Kuntari

DOI: https://doi.org/10.31290/jiki.v5i2.1492

Abstract

Sampai saat ini belum ada vaksin yang dapat melawan HIV/AIDS. Antiretroviral Agents (ARV) hanya dapat memberkan ketahanan hidup dengan memperlambat reproduksi virus. Tujuan review ini adalah menjabarkan faktor-faktor yang dapat mempengaruhi ketahanan hidup / survival (ODHA) setelah pemberian ARV. faktor yang dapat mempengaruhi ketahanan hidup / survival dari orang dengan HIV / AIDS (ODHA) selain pemberian ARV. Review ini dilakukan penulis pada Januari – Maret 2019, dengan menelusuri database diantaranya PubMed, Google scholar, dan open access science direct. Pada review ini telah dijelaskan berbagai faktor yang mempengaruhi ketahanan hidup ODHA yang menerima pengobatan ARV, diantaranya : jenis kelamin, usia, status gizi, kadar CD4 dan juga koinfeksi.

References

Arjun BY, Unnikrishnan B, Ramapuram JT, Thapar R, Mithra P, Kumar N, Madi D et al. (2015) ‘Factors Influencing Quality of Life among People Living with HIV in Coastal South India. Journal of the International Asso-ciation of Providers of AIDS Care.

Brinkhof, M. W. G., Pujades-rodriguez, M. and Egger, M. (2009) ‘Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings?: Systematic Review and Meta-Analysis’, 4(6).

Carvour, M. L. et al. (2015) ‘Differential survival for men and women with HIV/AIDS-related neurologic diag¬nos¬es’, PLoS ONE, 10(6), pp. 1–11.

Gupta A,NadkarniG, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011;6: 271–84.

Günthard, H. F. et al. (2016) ‘Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults’, JAMA. doi: 10.1001/jama. 2016.8900.

KaiserJD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. (2006)‘Micronutrient suppleme¬n¬tation in-creases CD4 count in HIV-infected individuals on highly active anti-retroviral therapy: a prospective, double-blinded, placebo-controlled trial.’, Journal of acquired immune deficiency syndromes (1999), 42(5): 523–528.

Kogoya, T., Demartoto, A. and Murti, B. (2017) ‘Survival Predictors of People Living with HIV / AIDS in Wamena , Papua’, Indonesian Journal of Medicine’. pp. 184–191.

Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS Lond Engl. 2003 Dec 5; 17(18):2593–601.

Mfinanga SG, Kirenga BJ, Chanda DM. (2014). Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis;14:563–71.

Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A. (2011) Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS Lond Engl. 25(17):2167–75.

Sterne JA, May M, Costagliola D, (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet;373:1352–63.

Tchouga B, Ekouevi D K, Balestre E dan Dabis F. (2016). ‘Mortality and survival patterns of people living with HIV-2’. Curr Opin HIV AIDS. 11(5): 537–544.

Zhang, G. et al. (2016) ‘Outcomes and factors associated with survival of patients with HIV/AIDS initiating antiretroviral treatment in Liangshan Prefecture, southwest of China: A retrospective cohort study from 2005 to 2013’, Medicine (United States), 95(27).

FAKTOR-FAKTOR YANG MEMENGARUHI KETAHANAN HIDUP PASIEN HIV/AIDS: A REVIEW

Abstract

References